|Articles|September 29, 2021
Treatment Considerations in Relapsed/Refractory Multiple Myeloma
Advertisement
This article discusses the current treatment landscape and therapeutic strategies for multiple myeloma as well as the various factors that influence treatment selection including a patient’s ability to tolerate therapy, treatment goals, line of therapy, nature of relapse, duration and depth of response, and adverse events from previous therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5

































